Who makes Flovent Diskus 100 µg?

Flovent Diskus 100 µg is developed by University of Florida.

What development phase is Flovent Diskus 100 µg in?

Flovent Diskus 100 µg is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Flovent Diskus 100 µg

University of Florida · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Flovent Diskus 100 µg
Also known as	fluticasone
Sponsor	University of Florida
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients (PHASE3)
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate (NA)
FACTO Study (Foster® As Complete Treatment Option) (PHASE4)
Dose-Response of Salmeterol in Children (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Flovent Diskus 100 µg CI brief — competitive landscape report
Flovent Diskus 100 µg updates RSS · CI watch RSS
University of Florida portfolio CI